{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:29:48Z","timestamp":1794061788922,"version":"4.8.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 109-2314-B-075-069"],"award-info":[{"award-number":["MOST 109-2314-B-075-069"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V111E-001-2"],"award-info":[{"award-number":["V111E-001-2"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Detection of driver gene mutations is important in advanced NSCLC. The cobas EGFR mutation test is a mutant allele-specific real-time PCR assay with limitation owing to its primer design. Next-generation sequencing-based assay has a higher mutation detection coverage; however, its clinical impact remains unclear. We retrospectively collected the records of stage IV NSCLC patients with wild-type EGFR tested by cobas test. FoundationOne CDx was used for comprehensive genomic profiles. We then evaluated the missed EGFR mutations by the cobas test. We studied 62 patients. The median age was 60 (range: 35\u201386\u00a0years). Most patients were male and 58.1% were smokers. 91.9% were adenocarcinomas. Of the 62 samples, 7 (11.3%) were detected with EGFR mutations by NGS. Among these overlooked EGFR mutations, five were exon 20 insertions, and two were exon 19 deletions. Two patients received EGFR TKIs and showed durable response with PFS 5.9\u00a0months and 10.1\u00a0months, respectively. Using NGS as the standard, the false-negative rate of the cobas EGFR mutation test was 11.3%\u2014in a population with a high prevalence of EGFR mutations. The most overlooked mutations were exon 20 insertions. A comprehensive EGFR mutation assay can provide significant benefits to patients with NSCLC.<\/jats:p>","DOI":"10.1038\/s41598-022-17394-7","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T10:03:15Z","timestamp":1660039395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Chia-I","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Lu","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Hui","family":"Shiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Hung","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Sheng","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsu-Ching","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hua","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"issue":"2","key":"17394_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 11(2), 121\u2013128 (2010).","journal-title":"Lancet Oncol."},{"issue":"2","key":"17394_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/annonc\/mdw611","volume":"28","author":"L Paz-Ares","year":"2017","unstructured":"Paz-Ares, L. et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial. Ann. Oncol. 28(2), 270\u2013277 (2017).","journal-title":"Ann. Oncol."},{"issue":"3","key":"17394_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239\u2013246 (2012).","journal-title":"Lancet Oncol."},{"issue":"1","key":"17394_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382(1), 41\u201350 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"17394_CR5","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon, B. J. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371(23), 2167\u20132177 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"17394_CR6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters, S. et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377(9), 829\u2013838 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"17394_CR7","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw, A. T. et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N. Engl. J. Med. 383(21), 2018\u20132029 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"17394_CR8","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","volume":"30","author":"AT Shaw","year":"2019","unstructured":"Shaw, A. T. et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): Updated results, including overall survival, from PROFILE 1001. Ann. Oncol. 30(7), 1121\u20131126 (2019).","journal-title":"Ann. Oncol."},{"key":"17394_CR9","unstructured":"Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., et al. NCCN Guidelines insights: Non-small cell lung cancer, Version 2.2021. J. Natl. Compr. Canc. Netw. 19(3), 254\u201366 (2021)."},{"key":"17394_CR10","doi-asserted-by":"crossref","unstructured":"Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(Suppl 4), iv192\u2013iv237 (2018).","DOI":"10.1093\/annonc\/mdy275"},{"issue":"2","key":"17394_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.annonc.2019.10.026","volume":"31","author":"K Park","year":"2020","unstructured":"Park, K. et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: A KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Ann. Oncol. 31(2), 191\u2013201 (2020).","journal-title":"Ann. Oncol."},{"issue":"3","key":"17394_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120852","volume":"10","author":"KH Hsu","year":"2015","unstructured":"Hsu, K. H. et al. Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan. PLoS ONE 10(3), e0120852 (2015).","journal-title":"PLoS ONE"},{"issue":"17","key":"17394_CR13","doi-asserted-by":"publisher","first-page":"4954","DOI":"10.1158\/1078-0432.CCR-07-1387","volume":"13","author":"W Pao","year":"2007","unstructured":"Pao, W. & Ladanyi, M. Epidermal growth factor receptor mutation testing in lung cancer: Searching for the ideal method. Clin. Cancer Res. 13(17), 4954\u20134955 (2007).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"17394_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/JTO.0000000000000041","volume":"9","author":"CH Chiu","year":"2014","unstructured":"Chiu, C. H. et al. Clinical characteristics and treatment outcomes of lung adenocarcinomas with discrepant EGFR mutation testing results derived from PCR-direct sequencing and real-time PCR-based assays. J. Thorac. Oncol. 9(1), 91\u201396 (2014).","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"17394_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/jclinpath-2012-201194","volume":"66","author":"G Ellison","year":"2013","unstructured":"Ellison, G. et al. EGFR mutation testing in lung cancer: A review of available methods and their use for analysis of tumour tissue and cytology samples. J. Clin. Pathol. 66(2), 79\u201389 (2013).","journal-title":"J. Clin. Pathol."},{"issue":"3","key":"17394_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/14737159.2017.1288568","volume":"17","author":"U Malapelle","year":"2017","unstructured":"Malapelle, U. et al. Profile of the Roche cobas(R) EGFR mutation test v2 for non-small cell lung cancer. Expert Rev. Mol. Diagn. 17(3), 209\u2013215 (2017).","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"6","key":"17394_CR17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/1759-7714.13797","volume":"12","author":"K Uchibori","year":"2021","unstructured":"Uchibori, K. et al. Clinical influence of switching companion diagnostic tests for EGFR-TKs from Therascreen to Cobas v2. Thorac. Cancer 12(6), 906\u2013913 (2021).","journal-title":"Thorac. Cancer"},{"issue":"4","key":"17394_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/JCMA.0000000000000277","volume":"83","author":"CI Shen","year":"2020","unstructured":"Shen, C. I., Ho, H. L., Yeh, Y. C., Chiu, C. H. & Chou, T. Y. Epidermal growth factor receptor mutations in non-small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reaction-based assays. J. Chin. Med. Assoc. 83(4), 345\u2013349 (2020).","journal-title":"J. Chin. Med. Assoc."},{"issue":"3","key":"17394_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"NI Lindeman","year":"2018","unstructured":"Lindeman, N. I. et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology. Arch. Pathol. Lab. Med. 142(3), 321\u2013346 (2018).","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"4","key":"17394_CR20","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/1759-7714.13786","volume":"12","author":"R Ariyasu","year":"2021","unstructured":"Ariyasu, R. et al. Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice. Thorac. Cancer 12(4), 504\u2013511 (2021).","journal-title":"Thorac. Cancer"},{"key":"17394_CR21","doi-asserted-by":"crossref","unstructured":"Rudzi\u0144ski, S., Szpechci\u0144ski, A., Moes-Sosnowska, J., Duk, K., Zdral, A., Lechowicz, U., et al. The EGFR mutation detection in NSCLC by next generation sequencing (NGS): Cons and pros. Eur. Respir. J. 54(suppl 63), PA4059 (2019).","DOI":"10.1183\/13993003.congress-2019.PA4059"},{"issue":"6","key":"17394_CR22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/14737159.2020.1724094","volume":"20","author":"S Torres","year":"2020","unstructured":"Torres, S. et al. A profile on cobas(R) EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer. Expert Rev. Mol. Diagn. 20(6), 575\u2013582 (2020).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"17394_CR23","doi-asserted-by":"crossref","unstructured":"Keppens, C., Scudder, S., Das, P., Palma, J., Wen, W., Normanno, N., et al. P3.02b-043 Inter-laboratory comparison of the Roche Cobas EGFR Mutation Test v2 in Plasma: Topic: EGFR biomarkers. J. Thorac. Oncol. 12(1), S1213 (2017).","DOI":"10.1016\/j.jtho.2016.11.1710"},{"issue":"2","key":"17394_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089518","volume":"9","author":"S Benlloch","year":"2014","unstructured":"Benlloch, S. et al. Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: Retrospective testing of specimens from the EURTAC trial. PLoS ONE 9(2), e89518 (2014).","journal-title":"PLoS ONE"},{"key":"17394_CR25","unstructured":"Roche Molecular Systems I. cobas EGFR Mutation Test v2. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf12\/P120019S007c.pdf (2015)."},{"issue":"3","key":"17394_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247620","volume":"16","author":"H Burnett","year":"2021","unstructured":"Burnett, H. et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review. PLoS ONE 16(3), e0247620 (2021).","journal-title":"PLoS ONE"},{"key":"17394_CR27","doi-asserted-by":"crossref","unstructured":"Bauml, J. M., Viteri, S., Minchom, A., Bazhenova, L., Ou, S., Schaffer, M., et al. FP07.12 Underdiagnosis of EGFR exon 20 insertion mutation variants: Estimates from NGS-based real-world datasets. J. Thorac. Oncol. 16(3), S208\u2013S9 (2021).","DOI":"10.1016\/j.jtho.2021.01.112"},{"issue":"6","key":"17394_CR28","doi-asserted-by":"publisher","first-page":"e620","DOI":"10.1016\/j.cllc.2019.06.018","volume":"20","author":"JY Wu","year":"2019","unstructured":"Wu, J. Y., Yu, C. J. & Shih, J. Y. Effectiveness of treatments for advanced non-small-cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations. Clin. Lung Cancer 20(6), e620\u2013e630 (2019).","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"17394_CR29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","volume":"12","author":"ME Arcila","year":"2013","unstructured":"Arcila, M. E. et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol. Cancer Ther. 12(2), 220\u2013229 (2013).","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"17394_CR30","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1158\/1535-7163.MCT-13-0192","volume":"12","author":"PJ Voon","year":"2013","unstructured":"Voon, P. J., Tsui, D. W., Rosenfeld, N. & Chin, T. M. EGFR exon 20 insertion A763\u2013Y764insFQEA and response to erlotinib\u2013Letter. Mol. Cancer Ther. 12(11), 2614\u20132615 (2013).","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"17394_CR31","volume":"1","author":"PENS Vasconcelos","year":"2020","unstructured":"Vasconcelos, P. E. N. S. et al. EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors. JTO Clin. Res. Rep. 1(3), 100051 (2020).","journal-title":"JTO Clin. Res. Rep."},{"issue":"30","key":"17394_CR32","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","volume":"39","author":"K Park","year":"2021","unstructured":"Park, K. et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase I study. J. Clin. Oncol. 39(30), 3391\u20133402 (2021).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"17394_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4761","volume":"7","author":"C Zhou","year":"2021","unstructured":"Zhou, C. et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: A phase 1\/2 open-label nonrandomized clinical trial. JAMA Oncol. 7(12), e214761 (2021).","journal-title":"JAMA Oncol."},{"key":"17394_CR34","unstructured":"FDA Approves tissue-based NGS companion diagnostic for Takeda\u2019s targeted therapy for NSCLC patients with EGFR exon20 insertion mutations. News release. Thermo Fisher Scientific. September 15, 2021. Accessed September 16, 2021. https:\/\/prn.to\/3CntcHX"},{"key":"17394_CR35","unstructured":"Guardant360\u00ae CDx Receives FDA Approval as Companion Diagnostic for Janssen\u2019s RYBREVANT\u2122 (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. News release. Guardant. May 21, 2021. https:\/\/investors.guardanthealth.com\/press-releases\/press-releases\/2021\/Guardant360-CDx-Receives-FDA-Approval-as-Companion-Diagnostic-for-Janssens-RYBREVANT-amivantamab-vmjw-for-Use-in-Patients-with-Advanced-Non-Small-Cell-Lung-Cancer-with-EGFR-Exon-20-Insertion-Mutations\/default.aspx"},{"issue":"1","key":"17394_CR36","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1186\/s12885-020-07240-2","volume":"20","author":"L Schluckebier","year":"2020","unstructured":"Schluckebier, L. et al. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. BMC Cancer 20(1), 875 (2020).","journal-title":"BMC Cancer"},{"key":"17394_CR37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.lungcan.2019.11.022","volume":"139","author":"AC Tan","year":"2020","unstructured":"Tan, A. C. et al. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Lung Cancer 139, 207\u2013215 (2020).","journal-title":"Lung Cancer"},{"key":"17394_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.19.00002","volume":"3","author":"L Steuten","year":"2019","unstructured":"Steuten, L., Goulart, B., Meropol, N. J., Pritchard, D. & Ramsey, S. D. Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer. JCO Clin. Cancer Inform. 3, 1\u201310 (2019).","journal-title":"JCO Clin. Cancer Inform."},{"key":"17394_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100487","volume":"25","author":"R Colomer","year":"2020","unstructured":"Colomer, R. et al. When should we order a next generation sequencing test in a patient with cancer?. EClinicalMedicine 25, 100487 (2020).","journal-title":"EClinicalMedicine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17394-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17394-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17394-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:48:09Z","timestamp":1669358889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17394-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["17394"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-17394-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"assertion":[{"value":"2 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CIS has received honoraria from Boehringer Ingelheim. THS reports non-financial support from Foundation Medicine, personal fees from Bristol-Myers Squibb, outside the submitted work. HSC reports personal fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, CStone, Eli Lilly, Merck Sharp & Dohme Corp, Novartis, Pfizer, Roche, outside the submitted work. CLC and CHC have received honoraria from AstraZeneca, Boehringer Ingelheim, Pfizer, and Roche. The other authors have no competing interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13566"}}